Downregulation of P-gp, Ras and p-ERK1/2 contributes to the arsenic trioxide-induced reduction in drug resistance towards doxorubicin in gastric cancer cell lines

Zhao,Yuan‑Yuan; Yu,Li; Liu,Bao‑Ling; He,Xin‑Jia; Zhang,Bi‑Yuan

doi:10.3892/mmr.2015.4367

Downregulation of P-gp, Ras and p-ERK1/2 contributes to the arsenic trioxide-induced reduction in drug resistance towards doxorubicin in gastric cancer cell lines

Authors:
- Yuan‑Yuan Zhao
- Li Yu
- Bao‑Ling Liu
- Xin‑Jia He
- Bi‑Yuan Zhang
View Affiliations

Affiliations: Department of Oncology, The Affiliated Hospital of Medical College, Qingdao University, Qingdao, Shandong 266000, P.R. China
Published online on: September 25, 2015 https://doi.org/10.3892/mmr.2015.4367
Pages: 7335-7343
Copyright: © Zhao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Multidrug resistance (MDR) to doxorubicin (DOX) limits its effectiveness against tumor cells. Arsenic trioxide (As2O3) has been reported to reduce MDR in various types of cancer, but the mechanisms involving Ras and p-glycoprotein (P-gp) remain to be fully elucidated. The objectives of the present study were to evaluate As2O3 in reversing MDR to DOX, and to identify the association in antitumor activities between the effectiveness of DOX and Ras/phosphorylated (p‑) extracellular signal‑regulated kinase (ERK)1/2 signaling in SGC7901/ADM and SGC7901/S human gastric cancer cell lines. Cytotoxicity and sensitivity towards As2O3 were assessed using non‑toxic and mildly‑toxic concentrations (0.1 and 0.5 µM, respectively). The reversing effect of As2O3 on MDR was investigated prior to and following treatment with a cytokine activation of the recombinant human granulocyte colony stimulating factor ERK pathway. The SGC7901/ADM and SGC7901/S cells had the same sensitivity to As2O3. The SGC7901/ADM cells were resistant to DOX and As2O3 treatment reduced the level of resistance to DOX (P<0.01). The expression of P‑glycoprotein (P-gp) in the SGC7901/ADM cells was higher than in the SGC7901/S cells (P<0.001). As2O3 treatment decreased the levels of P‑gp in a time‑ and dose‑dependent manner (P<0.01). The expression of Ras was higher in the SGC7901/ADM cells than in the SGC7901/S cells, while the expression of p‑ERK1/2 remained the same. As2O3 decreased the levels of Ras and p‑ERK1/2 (P<0.01). Following pretreatment with rhG‑CSF, the levels of Ras and p‑ERK1/2 were further decreased (P<0.01). Drug‑resistant gastric cancer cells had higher expression levels of P‑gp and Ras, but not of p‑ERK1/2. Non‑ and mildly‑toxic doses of As2O3 reduced MDR to DOX through Ras/p-ERK1/2 signaling.

View Figures

View References

1	Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar
2	Matsuda A and Machii R: Trends in stomach cancer mortality rates in Japan, USA, UK, France and Korea based on the WHO mortality database. Jpn J Clin Oncol. 42:1542012. View Article : Google Scholar : PubMed/NCBI
3	Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005. View Article : Google Scholar : PubMed/NCBI
4	Zheng LH, Bao YL, Wu Y, Yu CL, Meng X and Li YX: Cantharidin reverses multidrug resistance of human hepatoma HepG2/ADM cells via down-regulation of P-glycoprotein expression. Cancer Lett. 272:102–109. 2008. View Article : Google Scholar : PubMed/NCBI
5	Volm M and Mattern J: Resistance mechanisms and their regulation in lung cancer. Crit Rev Oncog. 7:227–244. 1996. View Article : Google Scholar : PubMed/NCBI
6	Mervis J: Ancient remedy performs new tricks. Science. 273:5781996. View Article : Google Scholar : PubMed/NCBI
7	Zhu J, Chen Z, Lallemand-Breitenbach V and de Thé H: How acute promyelocytic leukaemia revived arsenic. Nat Rev Cancer. 2:705–713. 2002. View Article : Google Scholar : PubMed/NCBI
8	Zhang TD, Chen GQ, Wang ZG, Wang ZY, Chen SJ and Chen Z: Arsenic trioxide, a therapeutic agent for APL. Oncogene. 20:7146–7153. 2001. View Article : Google Scholar : PubMed/NCBI
9	Lo-Coco F, Avvisati G, Vignetti M, Thiede C, Orlando SM, Iacobelli S, Ferrara F, Fazi P, Cicconi L, Di Bona E, et al: Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med. 369:111–121. 2013. View Article : Google Scholar : PubMed/NCBI
10	Murgo AJ: Clinical trials of arsenic trioxide in hematologic and solid tumors: Overview of the National Cancer Institute Cooperative Research and Development Studies. Oncologist. 6(Suppl 2): 22–28. 2001. View Article : Google Scholar : PubMed/NCBI
11	Lu J, Chew EH and Holmgren A: Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide. Proc Natl Acad Sci USA. 104:12288–12293. 2007. View Article : Google Scholar : PubMed/NCBI
12	Munshi NC: Arsenic trioxide: An emerging therapy for multiple myeloma. Oncologist. (6 Suppl 2): 17–21. 2001. View Article : Google Scholar : PubMed/NCBI
13	Maeda H, Hori S, Nishitoh H, Ichijo H, Ogawa O, Kakehi Y and Kakizuka A: Tumor growth inhibition by arsenic trioxide (As2O3) in the orthotopic metastasis model of androgen-independent prostate cancer. Cancer Res. 61:5432–5440. 2001.PubMed/NCBI
14	Shen ZY, Zhang Y, Chen JY, Chen MH, Shen J, Luo WH and Zeng Y: Intratumoral injection of arsenic to enhance antitumor efficacy in human esophageal carcinoma cell xenografts. Oncol Rep. 11:155–159. 2004.
15	Bornstein J, Sagi S, Haj A, Harroch J and Fares F: Arsenic Trioxide inhibits the growth of human ovarian carcinoma cell line. Gynecol Oncol. 99:726–729. 2005. View Article : Google Scholar : PubMed/NCBI
16	Woo SH, Park IC, Park MJ, Lee HC, Lee SJ, Chun YJ, Lee SH, Hong SI and Rhee CH: Arsenic trioxide induces apoptosis through a reactive oxygen species-dependent pathway and loss of mitochondrial membrane potential in HeLa cells. Int J Oncol. 21:57–63. 2002.PubMed/NCBI
17	Miller WH Jr, Schipper HM, Lee JS, Singer J and Waxman S: Mechanisms of action of arsenic trioxide. Cancer Res. 62:3893–3903. 2002.PubMed/NCBI
18	Pelicano H, Feng L, Zhou Y, Carew JS, Hileman EO, Plunkett W, Keating MJ and Huang P: Inhibition of mitochondrial respiration: a novel strategy to enhance drug-induced apoptosis in human leukemia cells by a reactive oxygen species-mediated mechanism. J Biol Chem. 278:37832–37839. 2003. View Article : Google Scholar : PubMed/NCBI
19	Eguchi R, Fujimori Y, Takeda H, Tabata C, Ohta T, Kuribayashi K, Fukuoka K and Nakano T: Arsenic trioxide induces apoptosis through JNK and ERK in human mesothelioma cells. J Cell Physiol. 226:762–768. 2011. View Article : Google Scholar
20	Xia J, Li Y, Yang Q, Mei C, Chen Z, Bao B, Ahmad A, Miele L, Sarkar FH and Wang Z: Arsenic trioxide inhibits cell growth and induces apoptosis through inactivation of notch signaling pathway in breast cancer. Int J Mol Sci. 13:9627–9641. 2012. View Article : Google Scholar : PubMed/NCBI
21	Xiao Z, Ding N, Xiao G, Wang S, Wu Y and Tang L: Reversal of multidrug resistance by gefitinib via RAF1/ERK pathway in pancreatic cancer cell line. Anat Rec (Hoboken). 295:2122–2128. 2012. View Article : Google Scholar
22	Zhao D, Jiang Y, Dong X, Liu Z, Qu B, Zhang Y, Ma N and Han Q: Arsenic trioxide reduces drug resistance to adriamycin in leukemic K562/A02 cells via multiple mechanisms. Biomed Pharmacother. 65:354–358. 2011. View Article : Google Scholar : PubMed/NCBI
23	Zhao Y, You H, Liu F, An H, Shi Y, Yu Q and Fan D: Differentially expressed gene profiles between multidrug resistant gastric adenocarcinoma cells and their parental cells. Cancer Lett. 185:211–218. 2002. View Article : Google Scholar : PubMed/NCBI
24	Che XF, Nakajima Y, Sumizawa T, Ikeda R, Ren XQ, Zheng CL, Mukai M, Furukawa T, Haraguchi M, Gao H, et al: Reversal of P-glycoprotein mediated multidrug resistance by a newly synthesized 1,4-benzothiazipine derivative, JTV-519. Cancer Lett. 187:111–119. 2002. View Article : Google Scholar : PubMed/NCBI
25	Wang R, Xia L, Gabrilove J, Waxman S and Jing Y: Downregulation of Mcl-1 through GSK-3β activation contributes to arsenic trioxide-induced apoptosis in acute myeloid leukemia cells. Leukemia. 27:315–324. 2013. View Article : Google Scholar
26	Brandstetter T, Ninci E, Falken U, Wagner E, Hess R and Bauknecht T: rhG-CSF affects genes involved in mitogen signalling and early gene expression in the ovarian cancer cell line HEY. Int J Cancer. 75:847–854. 1998. View Article : Google Scholar : PubMed/NCBI
27	Ricciardi MR, McQueen T, Chism D, Milella M, Estey E, Kaldjian E, Sebolt-Leopold J, Konopleva M and Andreeff M: Quantitative single cell determination of ERK phosphorylation and regulation in relapsed and refractory primary acute myeloid leukemia. Leukemia. 19:1543–1549. 2005. View Article : Google Scholar : PubMed/NCBI
28	Newman MJ, Rodarte JC, Benbatoul KD, Romano SJ, Zhang C, Krane S, Moran EJ, Uyeda RT, Dixon R, Guns ES, et al: Discovery and characterization of OC144-093, a novel inhibitor of P-glycoprotein-mediated multidrug resistance. Cancer Res. 60:2964–2972. 2000.PubMed/NCBI
29	Li Y, Qu X, Qu J, Zhang Y, Liu J, Teng Y, Hu X, Hou K and Liu Y: Arsenic trioxide induces apoptosis and G2/M phase arrest by inducing Cbl to inhibit PI3K/Akt signaling and thereby regulate p53 activation. Cancer Lett. 284:208–215. 2009. View Article : Google Scholar : PubMed/NCBI
30	Chen X, Zhang M and Liu LX: The overexpression of multidrug resistance-associated proteins and gankyrin contribute to arsenic trioxide resistance in liver and gastric cancer cells. Oncol Rep. 22:73–80. 2009.PubMed/NCBI
31	Liu Y, Zhang W, Zhang X, Qi Y, Huang D and Zhang Y: Arsenic trioxide inhibits invasion/migration in SGC-7901 cells by activating the reactive oxygen species-dependent cyclo-oxygenase-2/matrix metalloproteinase-2 pathway. Exp Biol Med (Maywood). 236:592–597. 2011. View Article : Google Scholar
32	Zhang G, Liu J, Zhang Y, Qu J, Xu L, Zheng H, Liu Y and Qu X: Cbl-b-dependent degradation of FLIP(L) is involved in ATO-induced autophagy in leukemic K562 and gastric cancer cells. FEBS Lett. 586:3104–3110. 2012. View Article : Google Scholar : PubMed/NCBI
33	Baguley BC: Multiple drug resistance mechanisms in cancer. Mol Biotechnol. 46:308–316. 2010. View Article : Google Scholar : PubMed/NCBI
34	Gillet JP and Gottesman MM: Mechanisms of multidrug resistance in cancer. Methods Mol Biol. 596:47–76. 2010. View Article : Google Scholar
35	Wong KA, Russo A, Wang X, Chen YJ, Lavie A and O'Bryan JP: A new dimension to Ras function: A novel role for nucleotide-free Ras in Class II phosphatidylinositol 3-kinase beta (PI3KC2β) regulation. PLoS One. 7:e453602012. View Article : Google Scholar
36	Karnoub AE and Weinberg RA: Ras oncogenes: Split personalities. Nat Rev Mol Cell Biol. 9:517–531. 2008. View Article : Google Scholar : PubMed/NCBI
37	Kindler HL, Aklilu M, Nattam S and Vokes EE: Arsenic trioxide in patients with adenocarcinoma of the pancreas refractory to gemcitabine: A phase II trial of the University of Chicago Phase II Consortium. Am J Clin Oncol. 31:553–556. 2008. View Article : Google Scholar : PubMed/NCBI
38	NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines)Gastric Cancer. 3rd edition. National Comprehensive Cancer Network; Fort Washington: 2015
39	Guo H, Sun F, Huang W, Liu Z, Zhang S, Zhou Q and Liang C: The effect of rhG-CSF on spleen transcriptome in mouse leukopenia model induced by cyclophosphamide. Immunopharmacol Immunotoxicol. 36:114–123. 2014. View Article : Google Scholar : PubMed/NCBI
40	Kumar J, Fraser FW, Riley C, Ahmed N, McCulloch DR and Ward AC: Granulocyte colony-stimulating factor receptor signalling via Janus kinase 2/signal transducer and activator of transcription 3 in ovarian cancer. Br J Cancer. 110:133–145. 2014. View Article : Google Scholar :